Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload
Status:
Terminated
Trial end date:
2011-08-09
Target enrollment:
Participant gender:
Summary
RATIONALE: Low dose deferasirox may be safe and effective in treating patients who have
undergone hematopoietic stem cell transplant and have iron overload.
PURPOSE: This pilot clinical trial studies safety and tolerability of deferasirox in
hematopoietic stem cell transplant recipients who have iron overload. Effect of low dose
deferasirox on labile plasma iron is also examined.